论文部分内容阅读
目的探讨苯扎贝特对中老年高血压代谢综合征患者各代谢因素的影响。方法将55例中老年高血压代谢综合征患者分为2组:苯扎贝特组28例给予缓释硝苯地平、苯扎贝特并饮食控制;对照组27例给予缓释硝苯地平、安慰剂并饮食控制。观察治疗前后血压、体质指数、血脂、空腹血糖、胰岛素、胰岛素抵抗指数及尿酸水平等变化。结果2组血压水平均有明显下降,苯扎贝特组治疗后舒张压降低较对照组显著(P<0.05);苯扎贝特组血甘油三酯、总胆固醇、低密度脂蛋白胆固醇水平明显降低(P<0.05或0.001),高密度脂蛋白胆固醇显著升高(P<0.05),空腹血糖及胰岛素浓度降低(P<0.05),胰岛素敏感性升高(P<0.05),血尿酸水平明显下降(P<0.01)。结论苯扎贝特有可能改善中老年高血压代谢综合征患者的多种代谢异常因素。
Objective To investigate the effects of bezafibrate on metabolic factors in elderly patients with metabolic syndrome. Methods Fifty-five elderly hypertensive metabolic syndrome patients were divided into two groups: 28 patients in the bezafibrate group were given sustained-release nifedipine and bezafibrate, and the diet was controlled. In the control group, 27 patients were given sustained-release nifedipine, Placebo and diet control. Blood pressure, body mass index, blood lipid, fasting blood glucose, insulin, insulin resistance index and uric acid level were observed before and after treatment. Results The levels of blood pressure were significantly decreased in both groups, and the diastolic blood pressure was lower in bezafibrate group than that in control group (P <0.05). The levels of triglyceride, total cholesterol and low density lipoprotein cholesterol in bezafibrate group were significantly higher (P <0.05 or 0.001), high density lipoprotein cholesterol (P <0.05), fasting blood glucose and insulin concentration (P <0.05), insulin sensitivity (P <0.05) Decreased (P <0.01). Conclusion Bezafibrate may improve many metabolic abnormalities in elderly patients with metabolic syndrome.